The antibody is expected to become the new crown strong medicine

, animal trials have shown that the team's meso-antibodies are promising to be a powerful drug for new coronary pneumonia, as well as providing short-term prevention. This is an important stage victory for scientific resistance to the epidemic. "If the outbreak were repeated in the winter, our middle antibodies might have been available by then, " Mr Xie said.
article points out that the selected median antibodies have two major applications: treatment and short-term prevention. At present, Xie Xiaoliang team and its partners are actively promoting clinical trials, full of confidence in the drug. The drug is producing GMP-grade drugs for clinical trials and is expected to be completed in July. Due to the small number of patients in China, clinical trials will be conducted in Australia and other countries under the coordination of Beijing Danshu Pharmaceutical Co., Ltd.
is in urgent need of strong drugs to treat neo-crown pneumonia. But at present, the two treatment methods that have been proved effective, small molecular drugs are only new to the old drugs, targeted, the current efficacy is limited, plasma therapy is effective, but due to the limited source of plasma, can not be widely used.
the effective part of plasma therapy is highly specific neutral antibodies. Antibody drugs are a large molecular drug that has been successfully used in AIDS, Ebola and other diseases, but in the past development took too long, it took months or even years, and the use of high-flung single-cell sequencing technology in the recovering patients' blood to find between the antibodies, can reduce the search time from year to month, the efficiency greatly improved.
Xie Xiaoliang's team used its expertise in single-cell genomics to select 8,558 viral protein binding antibody sequences from 60 patients in rehab and successfully identified 14 highly active meso-antibodies. Antibodies numbered BD-368-2 were prominent, with a semi-inhibitory concentration (IC50) of 1.2 ng/mL (8pM) in the fake virus experiment, and 15 ng/mL (100pM) in a true virus experiment conducted in the P3 laboratory of the Institute of Military Medicine.
's recently completed antiviral experiments in the antibody body have confirmed that the virus load was reduced 2,400 times by using the hACE2 genetically modified mouse model from Professor Qin Chuan of the Institute of Medical Experimental Animals of the Chinese Academy of Medical Sciences to treat BD-368-2 after infection with SARS-Cov-2. The injection of BD-368-2 can completely inhibit the viral infection of mouse models, and achieve preventive effect.
, a structural biologist with the
research team, and his team also used Cryo EM to obtain a high-resolution 3.8?3D structural density map of the new coronavirus Spike trimer and median antibody. The data show that the meso-antibody table on the antigen and the binding point of ACE2 re-match, thus revealing the structural basis of the meso-action. In addition, they also found that the use of antibody sequence to calculate the antibody and SARS virus neutral antibody in the structure of similarities to screen the new coronavirus neutral antibody, can greatly improve the screening efficiency.
Dong Chen, a member of the Chinese Academy of Sciences and dean of Tsinghua University's School of Medicine, commented: "This work is a major advance in the fight against new crowns, with great scientific and practical value, by screening high-quality mesobacteria and antibodies through cutting-edge high-flux single-cell sequencing techniques, combined with animal models, to confirm their excellent antiviral capabilities, to replace rehabilitation plasma therapy and overcome their defects, and to provide a powerful weapon for the treatment of new crown patients, especially those with severe conditions."
"Professor Xie Xiaoliang and his collaborators, using state-of-the-art single-cell sequencing technology, successfully screened neutral antibodies against the new coronary pneumonia virus from the blood of patients recovering in less than 3 months, and conducted preclinical animal experiments, which showed that the antibody molecule was very effective in suppressing and preventing infection with the new coronavirus in the short term," said Yan Feng, a member of the Chinese Academy of Sciences and deputy director of the Beijing Institute of Life Sciences. Xie Xiaoliang and his team's outstanding work, let us see the development of the first new corona pneumonia special effects drug hope, but also for mankind to finally defeat the new coronavirus brought a ray of light. The
began on January 27 and was supported by the Beijing Municipal Government and the Ministry of Science and Technology and the Ministry of Education. (Source: Cui Xueqin, China Science Daily)
related paper information: